Psychedelic drug developer Lykos could get lifeline from former Tesla board member
Former Tesla board member Antonio Gracias offers to rescue Lykos Therapeutics with $100M deal to save its psychedelic drug for PTSD. Read more here.
ground.newsI don’t have live access to the latest news right now. I can share a quick summary based on the most recent publicly reported items I’m aware of, and then I can look up current coverage if you’d like.
Key points about Antonio Gracias (recent coverage up to 2025–2026 context):
- Antonio Gracias is a longtime investor and former Tesla director, known for his role with Valor Equity Partners and his association with Elon Musk .
- Reports in 2025 highlighted Gracias being linked to potential involvement in psychedelic medicine ventures, including discussions around Lykos Therapeutics, with bids or takeover considerations mentioned in industry coverage .
- Various outlets have tracked his investment activities, board affiliations, and philanthropic involvements, including charitable gifts in higher education and research support mentioned in several feature pieces and profiles .
- For broader context, profiles and market-tracking resources list Gracias’ investment footprint and leadership roles, though specifics on current deals can vary by source and time .
Would you like me to fetch the latest news now and provide a concise, sourced summary with links? If you prefer, I can also focus on a specific aspect (e.g., business ventures, philanthropic work, or timeline of 2024–2025 activity) and present a brief, cited update.